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Summary
The G protein-coupled receptor oncogene (vGPCR) of the Kaposi’s sarcoma (KS) associated herpesvirus (KSHV), an
oncovirus implicated in angioproliferative neoplasms, induces angiogenesis by VEGF secretion. Accordingly, we found
that expression of vGPCR in human umbilical vein endothelial cells (HUVEC) leads to immortalization with constitutive
VEGF receptor-2/ KDR expression and activation. vGPCR immortalization was associated with anti-senescence mediated
by alternative lengthening of telomeres and an anti-apoptotic response mediated by vGPCR constitutive signaling and
KDR autocrine signaling leading to activation of the PI3K/AKT pathway. In the presence of the KS growth factor VEGF,
this mechanism can sustain suppression of signaling by the immortalizing gene. We conclude that vGPCR can cause an
oncogenic immortalizing event and recapitulate aspects of the KS angiogenic phenotype in human endothelial cells,
pointing to this gene as a pathogenic determinant of KSHV.
Introduction of endothelial origin, and inflammatory cell infiltration (Ensoli and
Sturzl, 1998; Gallo, 1998; Safai et al., 1985). Vascular endothelial
growth factor/vascular permeability factor (VEGF/VPF) plays aKaposi’s sarcoma associated herpesvirus (KSHV) or Human
Herpesvirus-8 (Chang et al., 1994; Mesri et al., 1996; Renne et pivotal role in the pathogenesis of KS since it is an angiogenic
and KS cell growth factor ubiquitously found in the lesionsal., 1996) is an oncogenic -2 herpesvirus implicated in three
AIDS associated malignancies: Kaposi’s sarcoma (KS) (Chang (Cornali et al., 1996; Masood et al., 1997), together with its
receptor-2 (VEGF-R2), also called kinase insert domain-con-et al., 1994), Primary effusion lymphoma (Cesarman et al., 1995),
and Multicentric Castleman’s disease (Soulier et al., 1995). KS taining receptor (KDR) (Brown et al., 1996). However, the trig-
gering mechanisms for the VEGF-mediated angiogenic re-is the most common cancer associated with AIDS (AIDS-KS)
(Antman and Chang, 2000; Gallo, 1998; Safai et al., 1985); and sponse in KS are still a matter of controversy (Gallo, 1998).
Cumulative evidence shows that KSHV fulfills all of the Koch-in its advanced disseminated form, it is still difficult to treat,
causing considerable morbidity and mortality. KS lesions can like postulates (Zur Hausen, 1999), defining it as an “angiogenic
oncovirus” necessary for KS (Boshoff and Weiss, 1998; Ganem,be found in the skin, lymph nodes, and GI tract and typically
present intense angiogenesis, proliferation of spindle-like cells 1998b): (1) KSHV is consistently found in the lesions of all clinical
S I G N I F I C A N C E
KSHV angiogenic oncogenes can cause endothelial cell transformation leading to Kaposi’s sarcoma (KS), an angioproliferative
disorder characterized by proliferation of spindle cells of endothelial origin expressing VEGF and its receptor-2/ KDR. However, since
these are lytic genes not expressed in most of KSHV-infected KS spindle cells, their role in oncogenesis has been unclear. Our
observation that vGPCR immortalizes HUVEC by autocrine KDR activation demonstrates the oncogenicity of KSHV lytic genes in
human endothelium since it shows that vGPCR expression is pro-angiogenic and pre-neoplastic, pointing to vGPCR and KDR activation
as targets for KS therapy. Evidence indicating that shutdown of vGPCR signaling can be overcome by VEGF, a KS growth factor,
provides a molecular explanation for the feasibility of a “hit and run” oncogenic event initiated by vGPCR in the multistep endothelial
oncogenesis process leading to KS.
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forms of KS (Chang et al., 1994; Moore and Chang, 1995); (2) (Cesarman et al., 2000; Yang et al., 2000). Expression of vGPCR
in endothelial cells has been shown to activate survival cas-KSHV infection precedes KS development and overlaps with
KS risks (Kedes et al., 1996; Moore et al., 1996b; Whitby et al., cades, to modulate the expression of angiogenesis regulating
genes and cytokines (Montaner et al., 2001; Pati et al., 2001;1995); (3) KSHV is found in KS-spindle and endothelial cells in
the lesions (Boshoff et al., 1995); (4) KSHV infection of endothe- Polson et al., 2002), and to activate pro-inflammatory transcrip-
tion (Chiou et al., 2002; Pati et al., 2001). These results and itslial cells, the cells thought to be pre-malignant for KS spindle
cells, was found to cause spindle cell transformation (Ciufo et pattern of expression in KSHV-infected endothelial-lineage cells
of KS lesions (Chiou et al., 2002; Kirshner et al., 1999; Staskusal., 2001; Lagunoff et al., 2002; Moses et al., 1999) and, in
some cases, immortalization (Flore et al., 1998) and angiogenic et al., 1997) indicate that vGPCR could participate in KS patho-
genesis. In the present study, we found that expression ofalterations such as upregulation of KDR (Flore et al., 1998;
Moses et al., 2002); (5) The KSHV genome (Russo et al., 1996) vGPCR is sufficient to cause endothelial cell immortalization
with constitutive expression and autocrine activation of VEGFcontains genes with the potential to induce cell transformation
(Bais et al., 1998; Friborg et al., 1999; Gao et al., 1997; Godden- receptor-2/KDR, a biological response related to the ability of
KSHV to induce endothelial oncogenesis and angiogenesis in KS.Kent et al., 1997; Lee et al., 1998; Muralidhar et al., 1998; Radkov
et al., 2000), immune deregulation (Moore et al., 1996a; Nicholas
et al., 1997), and angiogenicity (Aoki et al., 1999; Bais et al., Results
1998; Boshoff et al., 1997; Yang et al., 2000). Nevertheless,
KSHV can cause KS only in certain settings. According to the Expression of vGPCR in primary endothelial cells
causes immortalizationserological data, about 5% of the general population may be
infected with KSHV; however, the incidence of KS is below 1 To test the effect of sustained vGPCR expression in endothe-
lium, we transduced HUVEC cells at low passage with a neomy-in 100,000 in the general population. KS incidence increases
almost 20,000 times in AIDS, suggesting that immune deregula- cin-resistant retrovirus encoding an epitope-tagged version of
vGPCR (HA-vGPCR) using an EGFP-transducing virus as con-tion and HIV are important co-factors for KS- and KSHV-medi-
ated pathogenesis (Antman and Chang, 2000; Gallo, 1998). trol. After a single round of neomycin selection, we found that
100% of the cells expressed the transgene as determined byKSHV pathogenicity will be determined by the specific pattern
of viral gene expression and the specific cellular background UV fluorescent microscopy (EGFP) or anti-HA immunostaining
(Figures 1A and 1B). vGPCR-expressing cells showed strikinglyin which these genes are expressed, both of which are highly
dependent on host factors. Like other herpesviruses, KSHV can altered morphology. Both sub-confluent and confluent vGPCR-
EC were spindle shaped and refractile (Figure 1C). Confluentlead either to a latent infection or to a productive or lytic infection
that destroys the infected cell (Ganem, 1998b). The great major- cultures showed loss of both cell junctions and the typical cob-
blestone appearance (Figure 1C). vGPCR-EC also developedity of the cells in the KS lesions are latently infected with KSHV
(Staskus et al., 1997). Paradoxically, many of the KSHV genes characteristic cell extensions such as lamelipodia and pseudo-
podia best shown by confocal microscopy (Figure 1B). The mostfound to be transforming or pathogenic are lytic genes, which
are only expressed by a subset of cells in KS lesions productively striking consequence of vGPCR gene transduction was that the
vGPCR-EC were immortal in culture (Figure 1D). To date, theyinfected with KSHV (Staskus et al., 1997; Sun et al., 1999).
This observation is consistent with a role of latent genes in have been passaged every week for 2 years, maintaining the
same morphologic appearance and behavior in culture. In con-maintenance of the malignant phenotype and a role for lytic
genes expressed by productively infected cells in paracrine trast, and as expected for primary EC, both EGFP-EC and non-
transduced HUVEC became senescent, flattened, and went intoangiogenesis and the initiation of the phenotype (Ganem,
1998b). terminal replicative arrest between passages 12 and 14 (Figure
1D) . A Southern blot of the vGPCR-EC hybridized with a vGPCRCanonical latent and lytic KSHV infections are not highly
oncogenic as suggested by the low incidence of KS in the probe (data not shown) to detect the provirus showed that the
population by passage 20 was oligoclonal, with two major andgeneral KSHV-seropositive population, the low efficiency of EC
transformation in vitro (Flore et al., 1998), and the inability of three minor bands, indicating that immortalization was not the
consequence of a unique retroviral insertion event. AlthoughKSHV latent infection per se to transform endothelial cells (La-
gunoff et al., 2002). Thus, a critical question becomes how the the vGPCR-EC are immortal, they do not have all characteristics
of transformed cells since they cannot be cloned and they areinterplay between KSHV and host gene expression leads to
endothelial cell transformation and establishment of the KS an- not tumorigenic in immunodeficient mice (not shown). Further-
more, in culture medium, these cells divided at a rate similar togio-proliferative lesion. Therefore, we focused on angiogenic
lytic genes because their expression in endothelial cells could low passage HUVEC and had similar thymidine uptake levels
lead to oncogenic alterations. KSHV-ORF74 is an early lytic gene in serum free conditions (15,000  300 versus 12,500  250
encoding a G protein-coupled receptor (KSHV-GPCR/vGPCR) cpm/24 hr). These data are consistent with a multistep onco-
that shares a high degree of homology with the human CXCR2 genic process, with vGPCR expression providing the immor-
and CXCR1 (Cesarman et al., 1996), the receptors for the angio- talizing step.
genic chemokines IL-8 and Gro-, and can signal both in a
constitutive (ligand-independent) (Arvanitakis et al., 1997) and vGPCR immortalization of HUVEC occurs along
with expression of the VEGF receptorschemokine-activated manner (Gershengorn et al., 1998). Ex-
pression of vGPCR is sufficient to induce cell transformation To determine if vGPCR immortalization was associated with
high levels of VEGF receptor-2/KDR expression as seen in KSHVand VEGF-mediated angiogenesis in NIH3T3 cells (Bais et al.,
1998); and in transgenic animals expressing vGPCR in cells infected endothelial cells in vitro and in KS lesions, we carried
out flow-cytometric analysis of vGPCR-EC and HUVEC at multi-of the T cell lineage, to induce VEGF-driven KS-like lesions
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Figure 1. Retroviral transduction of HA-vGPCR to HUVEC leads to a spindle-cell phenotype and cell immortalization
A: (1) Phase-contrast microscopy of confluent cultures of HUVEC transduced with EGFP retrovirus after initial transduction. (2) UV microscopy of EGFP-
transduced HUVEC after a round of G418 selection.
B: Anti-HA immunohistochemistry of vGPCR-transduced HUVEC selected with G418 (1 and 2) and EC and IBMEC controls (3 and 4) showing the expression
of HA-vGPCR on the surface of the cells. For panels 1, 3, and 4, immunostaining developed with Vector red and cell nuclei stained with DAPI were visualized
by UV fluorescent microscopy. The panel 2 shows anti-HA immnostained vGPCR-EC cells single-developed with Vector Red and visualized by UV confocal
microscopy through a Z plane passing through the cell nucleus.
C: Phase contrast microscopy of sub-confluent (1 and 2) or confluent (3 and 4) cultures of EGFP-EC (Panels 1 and 3) or vGPCR-EC (Panels 2 and 4).
D: Logaritmic plot of cell growth. After neomycin selection (week 1), vGPCR-transduced cells, EGFP-transduced cells, or control HUVEC were passed at
1:3 (weeks 1–4) or 1:2 (from week five) weekly splitting ratio. The graph shows up to week 15 after G418 (current number of passage for vGPCR-EC is 160).
Similar data were obtained with an independently generated culture from the same viral batch and with different viral batches generated at a later date.
ple passages using a high-affinity anti-KDR monoclonal anti- immortalized endothelial cells (IBMEC) completely lacked ex-
pression of KDR and VEGF-R1. There is only one other knownbody (Clone 6.64) (Peichev et al., 2000). Figure 2A shows that,
as expected, low passage HUVEC displayed high levels of KDR example of a host-restricted endothelial viral oncogene that
immortalizes with maintenance of KDR expression: it is the Poly-expression in the majority of the cells. vGPCR-EC at passage
12, a passage at which control EGFP-EC started to senesce, oma middle T antigen (PymT) that, similarly to vGPCR, is an
endothelial cell-transforming signaling oncogene of a murineshowed high levels of KDR expression in 95% of the population
(Mean Fluorescence 1  10 E 7.48) (Figure 2A); this was main- virus (Pepper et al., 1995).
tained in immortalized cultures of vGPCR-EC (passage 40),
which also showed high levels of expression of KDR (Mean vGPCR induces telomere stabilization
by a telomerase-independent mechanismFluorescence 1  10 E 8.45) in the majority of the cells (91%).
Immunohistochemical studies shown in Figures 2B and 2C con- Cell immortalization is the consequence of overriding the normal
cellular mechanisms of senescence and apoptosis. To investi-firmed the flow cytometry results for KDR and also showed that
vGPCR cells also expressed high levels of the VEGF-R1/flt-1 gate the molecular basis of the immortalizing event induced by
vGPCR expression, we examined telomere maintenance and(Figure 2C). In addition to VEGF receptors, vGPCR-EC also
expressed the endothelial cell markers CD31/PECAM as deter- telomerase activity as well as the ability of vGPCR and KDR
to promote anti-apoptotic responses in the immortalized cells.mined by FACS and Tie-2 as determined by RT-PCR (not
shown). Expression of VEGF-R2/KDR and VEGF-R1/flt-1 is not Southern blots displayed on Figure 3 show that two indepen-
dently established vGPCR-EC cultures at passage 25 had telo-a general feature of immortalized EC. SV40 Large T antigen-
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Figure 2. vGPCR-mediated immortalization is associated with expression of VEGF receptors
A: Flow cytometric analysis of VEGF-R2/KDR expression comparing HUVEC (passage 4), vGPCR-EC passage 12, vGPCR-EC passage 40, or IBMEC. Cells
were maintained O.N. in serum free medium, harvested by collagenase digestion, and stained with control IgG or anti-KDR PE-labeled antibody (MoAb
6.64).
B and C: Immunohistochemical detection of VEGF-R2/KDR (B) and VEGF-R1/flt-1 (C) in vGPCR-EC (1 and 3), dermal microvascular EC (DMVEC) (positive
control) (2 and 5), and IBMEC (3 and 6). Bound antibody was detected by incubation with anti-mouse Ig labeled with alkaline phosphatase, developed
with Vector Red, and visualized by UV fluorescent microscopy. DAPI was used to stain cell nuclei.
mere lengths that did not differ significantly from that of passage (Colgin and Reddel, 1999). In the remaining 15%, telomere main-
tenance is achieved by a TERT-independent mechanism or ALT4 HUVEC (Figure 3A). In contrast, SV40 LT immortalized EC
(IBMEC) showed significantly shortened telomeres. These re- (alternative lengthening of telomeres) (Colgin and Reddel, 1999;
Reddel, 2000; Reddel et al., 2001). To test for TERT activity insults are consistent with the observation that vGPCR cells be-
came immortalized without going through a noticeable “cell the vGPCR-EC, we carried out a telomere repeat amplification
protocol (TRAP) assay (see Experimental Procedures). As showncrisis” triggered by telomere shortening and suggest that
vGPCR may immortalize EC by early activation of cellular mech- in Figure 3B, vGPCR-EC, unlike positive control 293T cells, did
not have detectable TERT activity. An RT-PCR assay showedanisms that regulate telomere length stability. In 85% of cell lines
and human cancers, telomere stability depends on activation of that 293T expressed a TERT transcript while vGPCR cells did
not (Figure 3C). These data suggest that in vGPCR immortalizedexpression of the catalytic subunit of the telomerase (TERT)
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Figure 3. vGPCR induces telomere stabilization by a telomerase-independent mechanism
A: DNA from HUVEC passage 4, two independently derived vGPCR-EC cultures at passage 25, HEK293T cells, or IBMECs were digested with HinfII/Rsa I,
separated in agarose gel, transferred to Hy-bond, hybridized with a telomeric probe, and developed by autoradiography.
B–C: TRAP assay of vGPCR-EC or HEK 293T cells (positive control); HI: heat inactivation; c() c() telomerase positive and negative lysates from the kit.
ITAS: internal template amplification sequence is an internal PCR control. TSR8: synthetic telomeric control. Telomerase positive lysates generate a telomeric
ladder which is amplified by PCR with labeled oligonucleotides, resolved by 12.5% PAGE, and developed by autoradiography.
C: RT-PCR for hTERT and -actin of vGPCR-EC and HEK 293T (293T) mRNA.
cells, telomere maintenance is carried out by a telomerase- kill HUVEC (Figures 4E and 4F). These results indicate that
sustained basal signaling through KDR is critical for the survivalindependent ALT mechanism (Reddel et al., 2001).
of immortal vGPCR-EC while it is not critical for the survival of
primary HUVEC; this suggests that sustained high levels of KDRSurvival of vGPCR-immortalized endothelial cells
expression and its activation play a role in maintenance of theis mediated by vGPCR and KDR signaling
immortalized phenotype in vGPCR-EC. Taken together, theseTo determine anti-apoptotic mechanisms involved in cell immor-
results show that both vGPCR and KDR constitutive activationtalization, we identified signaling mechanisms involved in
induce anti-apoptotic signaling cascades mediating survival ofvGPCR-EC survival. Figures 4A and 4D show that Gro-, a full
vGPCR-EC.agonist of the vGPCR (Gershengorn et al., 1998; Rosenkilde et
al., 1999) and VEGF, the KDR ligand, rescued vGPCR-EC from
starvation. As expected, VEGF was also able to rescue HUVEC Survival of immortalized vGPCR-EC is mediated by KDR
and vGPCR activation of the PI3K/AKT pathwaywhile the effects of Gro-were vGPCR specific. To demonstrate
if these receptors play an active role in vGPCR-EC survival, we Signaling by angiogenic receptors such as KDR in EC leads to
the activation of the Phosphoinositide 3-OH kinase (PI3K)/AKTsuppressed their signaling using the chemokine IP10, a vGPCR
reverse agonist (Geras-Raaka et al., 1998; Rosenkilde et al., anti-apoptotic pathway(Gerber et al., 1998). Recent overexpres-
sion studies using transient transfection have shown that1999), or PTK787, a small molecule inhibitor of the KDR tyrosine
kinase (Wood et al., 2000). As shown in Figures 4B and 4C, we vGPCR could activate AKT in EC (Montaner et al., 2001). Since
it is difficult to determine constitutive activation of kinases offound that IP10 suppressed vGPCR-EC survival in serum free
conditions by more than 80%, leading to more than a 2-fold rapid turnover such as AKT, we used the vGPCR ligand Gro-
and the KDR ligand VEGF to determine if vGPCR and KDR canincrease in apoptotic cell death. Although HUVEC may express
an IP10 receptor (Soejima and Rollins, 2001), IP10 did not alter activate the AKT signaling cascades in vGPCR-EC. Figure 5A
shows that vGPCR-EC treatment with Gro- or with VEGF leadsthe survival of control HUVEC (Figures 4B and 4C). We similarly
found that PTK787 suppressed survival and increased apopto- to phosphorylation of AKT. AKT phosphorylation was rapid,
occurring in less than 10 min, and vGPCR specific, as it wassis of vGPCR-EC (Figure 4E). Cell death and apoptosis were
induced at doses up to 100-fold lower than those required to not detected in control HUVEC. The immediate phosphorylation
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Figure 4. Survival of immortalized vGPCR-EC is mediated by KDR and vGPCR
A–F: Confluent cultures of HUVEC  or vGPCR-EC  were incubated overnight in serum free medium, alone (No Treatment, NT) or in the presence of Gro-
(25 nM), IP10 (300 nM), VEGF (100 ng/ml), or KDR inhibitor PTK787 at 0.1 ug/ml (1), 1 ug/ml (10), or 10 ug/ml (100). After 24 hr, cells were counted (A,
B, D, and E) or used for measuring apoptosis (C and F) by ELISA. Changes in cell apoptosis were calculated by normalizing the values of the O.D.s to the
O.D. value of the control experiment (NT). Bars indicate mean values of duplicates  range.
of AKT by vGPCR activation indicates that activation of this molecular effectiveness of the KDR inhibitors, we determined
pathway is a direct consequence of vGPCR signaling. To dem- in parallel their ability to suppress VEGF-induced tyrosine phos-
onstrate the role of AKT signaling on survival of immortalized phorylation of the KDR receptor and to suppress VEGF activa-
cells, we used the PI3K-specific inhibitor LY294002. Figure 5B tion of AKT (Figures 6B and 6C). We found that PTK completely
shows that in serum free media, LY294002 completely sup- suppressed VEGF-induced tyrosine phosphorylation of KDR
pressed vGPCR-EC survival and led to rapid apoptotic death while IMC-1C11 greatly decreased AKT phosphorylation medi-
at doses that did not affect HUVEC cell survival or apoptosis. ated by VEGF (Figures 6B and 6C). Taken together, these results
Additionally, Figure 5C shows that the inhibitor suppressed sur- indicate the presence of an autocrine loop. The fact that the
vival of vGPCR-EC in media containing FBS and bFGF (ECM). cell-permeable small molecule inhibitor PTK787 was much more
Taken together, the signaling and survival data suggest that effective than the antibody may indicate the existence of an
both vGPCR constitutive signaling and KDR activation mediate intracellular or so-called “private” autocrine loop, such as the
survival of vGPCR-EC by the PI3K/AKT pathway.
one recently described for endothelial hematopoietic progeni-
tors (Gerber et al., 2002). Autocrine activation of KDR could beAutocrine activation of KDR by increased VEGF
the consequence of VEGF overexpression caused by vGPCRsecretion mediates survival of vGPCR-EC
(Bais et al., 1998). To determine whether KDR basal survivalTo further study the nature of the basal KDR activation mecha-
signaling was promoted by an autocrine loop, we determinednism implicated in cell survival, we used two types of tools, the
VEGF levels by ELISA (Figure 6D). We found that vGPCR-ECKDR inhibitor PTK787 and a KDR-blocking antibody (IMC-1C11)
produced ten times more VEGF than HUVEC. Taken together,(Hunt, 2001). We found that the PTK inhibitor inhibited 85% and
these results show that vGPCR immortalization is partly driventhat the anti-KDR monoclonal antibody led to 55% (p  0.001)
by a VEGF-KDR autocrine loop induced by increased VEGFreduction of vGPCR-EC survival (Figure 6A), without signifi-
cantly affecting the survival of the HUVEC. To demonstrate the expression.
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Figure 5. Survival of immortalized vGPCR-EC is mediated by KDR and vGPCR activation of AKT
A: Confluent cells were starved O.N. in serum free medium and stimulated or not with Gro- (25 nM) or VEGF (100 ng/ml) for the indicated times and lysed
in electrophoresis cracking buffer. Total and phospho AKT in the cell lysates were detected by Western blot using anti-phospho antibodies and antibodies
to total AKT as indicated.
B–C: Confluent cultures of HUVEC  or vGPCR-EC  were incubated overnight in complete endothelial cell medium (ECM) or serum free medium (SFM)
as indicated in the figure, alone (No Treatment, NT) or in the presence of LY294002 (15 uM 1, or 150 uM 10). After 24 hr, cells were counted or used for
measuring apoptosis as in Figure 4. Changes in cell apoptosis were calculated by normalizing the values of the O.D.s to the O.D. value of the control
experiment (NT). Bars indicate mean values of duplicates  range.
VEGF activation of KDR can compensate for the lack of KS (Ganem, 1998a, 1998b; Boshoff and Weiss, 1998). In
this paper, we have shown that expression of the angiogenicof vGPCR signaling in vGPCR-EC
The fact that vGPCR immortalization involves autocrine activa- oncoprotein of KSHV, the vGPCR, in human endothelial cells
caused immortalization that was mediated by both constitutivetion of KDR and that KDR can be further activated by paracrine
addition of VEGF suggests that KDR may provide a VEGF- vGPCR signaling and autocrine-KDR signaling, leading to down-
stream activation of the pro-survival molecule AKT. This identi-dependent pathway able to complement the absence of vGPCR
survival signaling during viral latency. This could explain the fies vGPCR as a KSHV gene that can deliver an immortalizing
oncogenic hit and activate an angiogenic phenotype in targetobservations that vGPCR itself is not expressed in the majority of
KSHV-transformed cells of KS lesions or in KSHV-transformed endothelial cells.
Other viral oncogenes, such as SV40 Large T, HPV-16 E6/endothelial cells and that KSHV-transformed cells are strictly
dependent on external VEGF for survival. To test this hypothesis, E7 Adeno E1A, cause cell immortalization by inhibiting the activ-
ity of tumor supressor genes (Nevins and Vogt, 1996; Zur Hau-we studied the effect of exogenous VEGF in the presence of
IP10, which completely shuts down vGPCR signaling. As shown sen, 1999), which leads to unrestricted cell growth; this, in turn,
causes telomere shortening and cell crisis that is resolved byin Figure 7A, VEGF counteracted the effect of IP10, increasing
cell survival above that of nontreated cells and suppressing activation of telomerase. vGPCR appears to belong to a cate-
gory of cell-restricted signaling oncogenes, such as Polyomaapoptosis.
middle T (Pepper et al., 1995) and HTLV-1 Tax (Yoshida, 1999),
that can immortalize virus-infected cells by promotion of cell-Discussion
specific anti-senescent, anti-apoptotic, and autocrine re-
sponses. Since in our studies immortalization occurred withoutMajor unresolved issues in KS pathogenesis include the origin
of the VEGF-dependent angiogenic and malignant phenotype noticeable cell crisis and telomere shortening, we conclude that
vGPCR acts early in the oncogenesis process by activatingof the lesions (Gallo, 1998) and the precise mechanistic role of
KSHV infection, an absolute requirement for the development anti-senescence and anti-apoptotic mechanisms. Our data also
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Figure 6. Autocrine activation of KDR by increased VEGF secretion mediates survival of vGPCR-EC
A: Specific inhibition of cell survival by the KDR tyrosine kinase inhibitor PTK787 (upper panel) and the anti-KDR blocking antibody IMC-1C11 (lower panel):
confluent cultures of vGPCR-EC or HUVEC were incubated in serum free medium as indicated alone (No Treatment, NT) or in the presence of KDR inhibitor
PTK787 at 0.1 ug/ml (1) (upper panel), or the IMC-1C11 antibody at 2.5 ug/ml (lower panel) as indicated. After 24 hr of treatment, media were replaced
by ECM containing wst-1 cell proliferation reagent and incubated at 37	C for 30 min. Formation of formazan by living cells was measured at O.D. 450 nm.
Bars indicate mean values of duplicates  range. HUVEC , vGPCR-EC .
B: Confluent cultures maintained O.N. in serum free media were pretreated for 1 hr with the inhibitor prior to the addition of VEGF at 100 ng/ml for 10 min.
Cells were lysed, and KDR was immunoprecipitated with an anti-flk-1 antibody, Western blotted, and developed with an anti-Phospho tyrosine monoclonal
antibody as described in Experimental Procedures.
C: Confluent cultures maintained O.N. in serum free media were treated or not with VEGF at 100 ng/ml for 10 min with or without the addition of 2.5 ug/
ml of IMC-1C11 antibody. Cells were lysed, and total and phospho AKT were detected by Western blot using anti-phospho antibodies and antibodies to
total AKT as indicated.
D: Stable vGPCR expression in HUVEC leads to increased VEGF secretion: VEGF in post-culture supernatants obtained by 48 hr incubation with ECM was
measured using an ELISA kit. Values were normalized to number of cells.
suggest that the endothelial-immortalizing activity of vGPCR is the survival experiments in which vGPCR-EC are compared to
HUVEC. Although HUVEC are the best “formal” control becauserelated to its ability to induce an angiogenic phenotype since
we found that KDR activation, in addition to vGPCR expression, they are the nontransduced origin of vGPCR-EC cells, they are
not a perfect control because they are mortal cells with normalwas necessary to mediate the survival arm of the immortalized
phenotype. Moreover, since VEGF is known to be anti-senes- endothelial physiology. Studies with many small molecule inhibi-
tors have shown that oncogenically modified cells are in a deli-cent in EC (Watanabe et al., 1997), it is possible that EC immor-
talization is maintained by KDR signaling. Constitutive KDR ex- cate “balancing act” and are more vulnerable than normal cells
to inhibition of the signaling pathways that support their unlim-pression in vGPCR-immortalized EC can be related to the
existence of upregulation mechanisms. Autocrine VEGF has ited survival. This is also the case for vGPCR-EC, which are
very sensitive to vGPCR inhibition and are more sensitive thanbeen shown in other systems (Weisz et al., 2001) to upregulate
KDR expression, and we have shown with a heterologous sys- HUVEC to inhibition of AKT and KDR. Their increased sensitivity
to KDR inhibition coupled with their VEGF secretion stronglytem not expressing KDR that vGPCR can promote transcription
from the KDR promoter in the presence of endothelial-specific point to the existence of an autocrine loop. The fact that the
small molecule inhibitor PTK787 is more effective than the KDR-transcription factors (A.V.G. and E.A.M., unpublished data).
A key aspect of the studies reported in this manuscript are blocking antibody could be an indication of intracellular KDR
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Figure 7. VEGF activation of KDR can compensate for the lack of vGPCR signaling in vGPCR-EC
A: Confluent cultures of vGPCR-EC or HUVEC were incubated overnight in serum free medium, alone or in the presence of IP10 (300 nM) or VEGF at 100
ng/ml. After 24 hr, cells were counted or used for measuring apoptosis as indicated. Changes in cell apoptosis were calculated by normalizing the value
of the O.D.s to the O.D. value of the control experiment (no additions). Bars indicate mean values of duplicates  range. HUVEC , vGPCR-EC .
B: Model for vGPCR “hit and run” immortalization and paracrine activation of angiogenesis in KS pathogenesis: during lytic infection, vGPCR expression in
EC could lead to the establishment of a VEGF–KDR loop which is oncogenic, and to increased secretion of VEGF which can have paracrine angiogenic
activity. If the cell does not complete the lytic cycle (abortive lytic replication 
 Lytic*), it can become transformed due to the carcinogenicity of lytic
gene expression, including vGPCR-mediated immortalization, and switch to the latent status with shutdown of lytic gene expression including vGPCR. This
leads to strong VEGF dependence that should be supplied paracrinally.
activation. Such a private or internal autocrine loop has recently to mice endothelium, it was recently found that vGPCR is the
only KSHV gene able to provoke KS-like lesions and that it canbeen described for endothelial lineage bone marrow hematopoi-
etic progenitors (Gerber et al., 2002). The other possibility is paracrinally support KSHV latent gene tumorigenesis (Montaner
et al., 2003).that vGPCR, as described for other GPCRs, could directly trans-
activate KDR tyrosine phosphorylation (Pierce et al., 2001). Our finding that vGPCR expression increased VEGF secre-
tion in immortalized human endothelial cells (Figure 6) supportsThe finding that KSHV, an endothelial cell-transforming vi-
rus, encodes a gene with potential for endothelial immortaliza- the notion that in lytically infected cells of the KS lesion, vGPCR
could activate paracrine angiogenesis and spindle cell prolifera-tion and KDR autocrine activation has important implications
for KS pathogenesis and the identification of new therapeutic tion (Bais et al., 1998; Cesarman et al., 2000). It also explains
the ability of vGPCR-expressing endothelial cells for paracrineapproaches for AIDS-KS. It is consistent with new reports show-
ing the molecular and pathogenic alterations that vGPCR causes activation of angiogenesis and the promotion of the tumorigenic
potential of latent genes (Montaner et al., 2003).specifically in endothelial lineage cells in vitro (Polson et al.,
2002) and in vivo. Using avian retrovirus-mediated gene transfer Assigning a role for a KSHV angiogenic gene such as vGPCR
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in direct oncogenesis (Bais et al., 1998) or in the initiation of Our results show that G protein-coupled receptor signaling
KS sarcomagenesis (Montaner et al., 2003; Hayward, 2003) is can promote an anti-senescence response with lifespan exten-
complicated by the fact that it is an early lytic gene not ex- sion in endothelial cells, which is associated with KDR expres-
pressed in latently infected spindle cells composing the majority sion and activation. This points to a novel mechanism for the
of the malignant cells of KS tumors (Ganem, 1998b; Kirshner regulation of angiogenesis by GPCRs in general and angiogenic
et al., 1999; Staskus et al., 1997). However, at the same time, chemokines in particular. The observation that vGPCR could
there are reports indicating that expression of the KSHV latent determine the ability of KSHV for human endothelial immortali-
program found in malignant KS cells cannot transform endothe- zation and KDR activation warrants further studies on the role
lial cells (Lagunoff et al., 2002), as well as recent findings show- of this viral gene in KS pathogenesis and sets forth the possibility
ing the inability of KSHV latent genes to initiate KS sarcomagen- of targeting vGPCR and the VEGF-KDR activation axis to treat
esis by endothelial infection in mice (Montaner et al., 2003). and prevent KSHV-induced oncogenesis.
This paradox indicates that expression of KSHV oncogenic lytic
Experimental proceduresgenes may not always lead to viral progeny and cell killing
and indicates that not all KSHV genes that participate in the
Vector constructiononcogenesis process are expressed in the malignant KS cells.
The retroviral vectors used were a modification of the pLXCN vector (CMV
The mechanism that we describe for vGPCR immortalization IE driving expression) from Clontech in which the polylinker was expanded
involving KDR autocrine activation is compatible with such a (pLXCN2.0). The two different inserts used in this paper (HA-vGPCR and
modality of hit and run oncogenicity (Figure 7B), and it is sup- EGFP) were subcloned into the HindIII/NotI sites of the pLCNX2.0 polylinker.
HA-vGPCR coding HindIII/NotI fragment was taken from the pCEFLHA-ported by data showing that shutdown of vGPCR signaling
vGPCR vector (Bais et al., 1998). EGFP coding HindIII/NotI fragments werein vGPCR-EC is compensated by external VEGF (Figure 7A).
taken from p-N1-EGFP vector (Clontech).According to our findings, the lack of expression of vGPCR in
transformed cells of KS lesions latently infected with KSHV
Retroviral transduction of HUVEC
could be compensated by paracrine VEGF, which could be Retroviral stocks were obtained using the Ampho-Phoenix cells from Dr.
provided in part by lytically infected cells expressing vGPCR Garry Nolan, Stanford University, obtained through ATCC, following the
(Bais et al., 1998; Montaner et al., 2003). The high levels of KDR protocols of public access at the Nolan Lab (website http://www.stanford.
edu/group/nolan/). Passage 3 and 4 HUVEC obtained routinely at S.R. Labexpression and VEGF dependence of KS lesions (Brown et al.,
using standard methods were infected with retroviral stocks in the presence1996; Cornali et al., 1996) and some KSHV-transformed endo-
of polybrene (4 ug/ml). Once expression of the EGFP transgene was verified,thelial cells (Flore et al., 1998; Masood et al., 2002) can be
cells were passaged into a G418 containing medium.explained on the basis of this mechanism of vGPCR autocrine
immortalization followed by vGPCR shutdown (Figure 7B). In Culture of HUVEC and transduced cells
addition to VEGF, KSHV latent expression could compensate HUVEC were cultured in gelatin-coated plates in ECM medium: M199 (Bio-
anti-senescent and anti-apoptotic effects of vGPCR. LANA is Whittaker), 20% FCS (Gemini), 2 ng/ml of bFGF (PeProtech) and antibiotics
(penicillin and streptomycin). Retrovirally transduced endothelial cells wereknown to promote telomerase transcription (Knight et al., 2001),
grown in the same medium with the addition of G418 (Gibco-BRL). Forwhile vFLIP can suppress apoptosis by NFkB activation (Liu et
serum free conditions, cells were incubated with X-VIVO 20 medium (Bio-al., 2002). A similar mechanism of hit and run autocrine immor-
Whittaker).talization has been proposed for HTLV-1 Tax, which immortal-
izes T cells by creation of an IL-2/IL-2R autocrine loop, but is Immunohistochemistry
deleted from the provirus in HTLV-1-transformed IL-2-depen- The cells were cultured on Labtek-Nunc chamber slides, coated with 0.2%
dent adult T cell lymphoma cells (Cesarman and Mesri, 1999; gelatin, and live-stained with the antibodies as follows: After cooling to 4	C,
Yoshida, 1999). the medium was removed and cells were washed once with DMEM before
blocking for 30 min in DMEM, 10% goat serum at 4	C. After a wash withThe model depicted in Figure 7 predicts that expression of
cold DMEM, the cell were incubated with the antibodies at 1 ug/ml (anti-KSHV lytic phase angiogenic genes and signaling oncogenes
HA: Covance-Babco, antiFlt-1 MoAb 6.12 and IMC-1C11 anti-KDR fromsuch as K1 (Lagunoff et al., 1999; Lee et al., 1998), vIL-6 (Aoki
Imclone) for 1 hr at 4	C and washed three times with cold DMEM. After
et al., 1999), and vGPCR in KSHV-infected cells that do not washing, cells were fixed with 3.7% PBS formalin and permeabilized with
complete the lytic cycle is an event with high oncogenic risk. methanol and acetone for 1 min each. After drying the slides, cells were
The probability of such an event is consistent with the low rehydrated in PBS and blocked with PBS, 10% Goat serum. The secondary
antibody, goat anti-mouse conjugated with alkaline phosphatase (Southernincidence of KS in the general infected population (Antman and
Biotech) was applied and incubated in 10% goat serum at 37	C for 1 hr.Chang, 2000) and the low transforming potential of the virus
The slides were washed three times and the color reaction with Vector(Flore et al., 1998; Lagunoff et al., 2002). The probability of
Red substrate kit was done according to the instructions provided by theabortive lytic infections such as the one described in Figure 7B
manufacturer. The cells were rinsed with water and counterstained with 0.5
is greatly increased with viral reactivation and de novo infection ug/ml DAPI in water for 5 min and rinsed with tap water. The slides were
with KSHV. Accordingly, KS incidence increases with post- dehydrated and mounted. The pictures were taken on a Zeiss Axioskop or
transplant immunosupression and AIDS (Gallo, 1998). These with a Zeiss confocal microscope.
pathologies are associated with decreases in immune surveil-
Cytofluorometrylance, inflammation, or the presence of HIV angiogenic mole-
For detection of surface of KDR expression, cells dislodged by collagenasecules such as Tat, which have been related to increased KSHV
treatment were incubated with phycoerythrin (PE)-labeled high-affinity, non-reactivation (Antman and Chang, 2000; Ensoli et al., 2001). Con-
neutralizing MoAbs to KDR clone 6.64 (ImClone Systems, New York, New
versely, drugs that block KSHV replication such as gancyclovir, York) (Peichev et al., 2000) for 20 min. The number of positive cells was
and immune recovery, although they do not act in latently in- compared to immunoglobulin G isotype control (PE; Immunotech, Marseille,
fected cells, have been shown to reduce KS incidence among France) and determined using Coulter Elite flow cytometer (COULTER, Hia-
leah, Florida).AIDS patients (Antman and Chang, 2000).
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Telomere length assay, telomerase activity, and TERT expression SDS-PAGE sample buffer, boiled at 95	C for 5 min, separated by SDS-
Seven and a half micrograms of Genomic DNA of each cell line was digested PAGE, and transferred to nitrocellulose membrane. Phosphotyrosine was
2 hr with 30 U of RsaI and 30 U of HinfII. Telomere length was measured detected with a monoclonal antibody (Upstate) and developed with anti-
by Southern blot using the telomere-specific oligonucleotide (TTAGG)4 and mouse IgG peroxidase (Cappel) and an ECL kit (Amersham).
hybridized following the protocol described in Bryant et al. (1997). TRAP
assay was performed using the TRAPeze Telomerase detection kit (Intergen VEGF determination by ELISA
Company, Cat. # S7700) and following a standard protocol provided with Human VEGF was measured in post culture supernatants obtained after 48
the kit. This assay measures the activity of telomerase in cell extracts by hr of incubation in ECM. VEGF was quantified using an R&D Quantikine kit.
determining its ability to oligomerize telomeric oligonucleotides. The collec- Samples were analyzed in duplicate. Experiments were repeated two times.
tion of oligomers is amplified by PCR using P-32-labeled primers, resolved
in a 12.5% polyacrilamide gel and developed by autoradiography. hTERT Acknowledgments
expression was evaluated by RT-PCR using Superscript RT (GIBCO-BRL)
and standard techniques. The TERT-specific primers employed were: 5 The authors would like to thank Dr. Marcelo Nocciari for his advice and help
primer CGGAAGAGTGTCTGGAGCAA, 3 primer GGATGAAGCGGAGTCT with various techniques, Joan Pillitieri for technical support, and Dr. Ethel
GGA. For -actin amplification, we employed primers supplied by Stra- Cesarman for her constant encouragement and advice. This work was sup-
tagene. ported through grants to E.A.M. from the American Cancer Society RPG-
99-207-01-MBC, National Institutes of Allergy and Infectious Disease (AI-
Thymidine incorporation 391920), National Cancer Institute (CA-75918), American Heart Association
Cells were seeded in 96-well plates, coated with 2% gelatin, at 10,000 cells (0140202N), The Dorothy Rodbell Cohen Foundation for Sarcoma Research,
per well. After overnight growth, the cells were starved in X-VIVO 20 with The New York Community Trust, and The Charles Offin Charitable Trust.
0.5% BSA and 3-H Thymidine (NEN) was added. After 24 hr incubation, the We would like to also acknowledge Drs. Hsing-Jien Kung and Paul A. Luciw
cells were frozen twice at 70	C to break up the cells. The cellular DNA at the University of California, Davis for helpful advice and providing re-
was precipitated on glass fiber filters (Wallac) and the 3-H activity was sources via the NCI grant R01-CA91574 (to H.-J.K.).
measured in a scintillation counter.
Cell survival and apoptosis assays
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